Targeted degradation of USP7 in solid cancer cells reveals distinct effects of deubiquitinase degraders and inhibitors

dc.contributor.authorKlink, Nikolas
dc.contributor.authorUrban, Sebastian
dc.contributor.authorSeier, Johanna A.
dc.contributor.authorAdhikari, Bikash
dc.contributor.authorSchwalm, Martin P.
dc.contributor.authorMüller, Juliane
dc.contributor.authorDorsch, Madeleine
dc.contributor.authorSteinbach, Philine
dc.contributor.authorJung, Jennifer
dc.contributor.authorVogt, Markus
dc.contributor.authorKaschani, Farnusch
dc.contributor.authorKoch, Johannes
dc.contributor.authorFührer, Siska
dc.contributor.authorKaiser, Markus
dc.contributor.authorSchulze, Nina
dc.contributor.authorKnapp, Stefan
dc.contributor.authorWolf, Elmar
dc.contributor.authorPaschen, Annette
dc.contributor.authorGrüner, Barbara M.
dc.contributor.authorGersch, Malte
dc.date.accessioned2026-07-20T08:13:53Z
dc.date.issued2026-05-13
dc.description.abstractProteolysis-targeting chimeras (PROTACs) co-op the ubiquitin system for targeted protein degradation, creating opportunities to interrogate cellular functions of proteins through “chemical knockdown”. However, matched pairs of protein degraders and inhibitors, that possess high specificity and chemical complementarity, for individual components of the ubiquitin system have remained scarce. This includes reagents to modulate activity and abundance of deubiquitinases (DUBs). Here, using an integrated chemical biology approach, we explore cellular functions of the DUB USP7 as a case study by comparing inhibition and degradation in melanoma and pancreatic cancer cells. Through the synthesis of a degrader library, we identify and characterize potent USP7 PROTACs for each cancer type. Proteomic and cellular analyses reveal that selective USP7 degradation modulates both shared and distinct protein sets across both cancers without affecting cell growth. In contrast, prolonged inhibitor treatment induces USP7-independent proteomic and metabolic dysregulation, highlighting important caveats for the cellular use of hydroxypiperidine-based USP7 inhibitors. Collectively, our work provides a comprehensively characterized chemical toolbox to distinguish on-target phenotypes which will aid the understanding of USP7 in malignant diseases. More broadly, our data emphasize the importance of increased specificity via PROTAC-mediated degradation and the potential of this modality to elucidate cell-line specific functions of DUBs.en
dc.identifier.doi10.1038/s41467-026-72295-x
dc.identifier.issn2041-1723
dc.identifier.urihttp://hdl.handle.net/2003/45005
dc.language.isoen
dc.publisherSpringer Science and Business Media LLC
dc.relation.ispartofNature Communications
dc.relation.ispartofseriesNature communications; 17
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.ddc570
dc.subject.ddc540
dc.titleTargeted degradation of USP7 in solid cancer cells reveals distinct effects of deubiquitinase degraders and inhibitorsen
dc.typeText
dc.type.publicationtypeArticle
dcterms.accessRightsopen access
eldorado.dnb.deposittrue
eldorado.doi.registerfalse
eldorado.secondarypublicationtrue
eldorado.secondarypublication.primarycitationKlink, N., Urban, S., Seier, J.A. et al. Targeted degradation of USP7 in solid cancer cells reveals distinct effects of deubiquitinase degraders and inhibitors. Nat Commun 17, 4331 (2026). https://doi.org/10.1038/s41467-026-72295-x
eldorado.secondarypublication.primaryidentifierhttps://doi.org/10.1038/s41467-026-72295-x
oaire.citation.issue1
oaire.citation.volume17

Dateien

Originalbündel

Gerade angezeigt 1 - 1 von 1
Lade...
Vorschaubild
Name:
s41467-026-72295-x.pdf
Größe:
4.29 MB
Format:
Adobe Portable Document Format
Beschreibung:
DNB

Lizenzbündel

Gerade angezeigt 1 - 1 von 1
Lade...
Vorschaubild
Name:
license.txt
Größe:
4.82 KB
Format:
Item-specific license agreed upon to submission
Beschreibung: